权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership

1/2 药物开发和能力建设：UCR/CoH-CCC 合作伙伴关系

基本信息

批准号：
10006525
负责人：
ERNEST MARTINEZ
金额：
$ 24.19万
依托单位：
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-09-02 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10006525
关键词：
Acetylation Address Affect African American American Antelopes Antineoplastic Agents Award Bioinformatics California Cell Line Cities City of Hope Comprehensive Cancer Center Clinical Collaborations Color Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility Data Development Drug Design Drug Targeting Drug resistance Education Engineering Ensure European Faculty Fellowship Fostering Funding Goals Grant Hispanic Americans Hispanics Individual Inequality Infrastructure Institution Investments Joints Latina Latino Los Angeles Malignant Neoplasms Master&apos s Degree Mentors Mentorship Minority Mitochondrial Proteins Not Hispanic or Latino Participant Patients Pharmaceutical Preparations Phase Physicians Population Postdoctoral Fellow Precision Medicine Initiative Reporting Research Personnel Resources Scientist Societies Students System Testing Therapeutic Therapeutic Agents Tissues Toxic effect Training Training Programs United States United States Food and Drug Administration United States National Institutes of Health Universities Woman Work anticancer research cancer health disparity clinical translation clinical trial participant disparity reduction drug development drug discovery ethnic diversity malignant breast neoplasm manufacturing facility medical schools men minority communities news next generation novel therapeutics outcome forecast phase 1 testing precision medicine programs screening success therapeutic development training opportunity triple-negative invasive breast carcinoma

项目摘要

ABSTRACT Cancer drugs in the United States are almost exclusively developed by, tested in, and optimized for European- Americans. Disparities in U.S. drug development are the result of long-standing inequalities that occur throughout the entire drug discovery pipeline. Only a small number of basic, translational and clinical scientists are Latino/Hispanic or Black/African-American. Less than 2-5% of trial participants are Latino/Hispanic or Black/African-American. Yet, in spite of a lack of data, new drugs are approved by the U.S. Food and Drug Administration (FDA) and subsequently prescribed for Latino/Hispanic or Black/African-American patients, without sufficient testing. It is unacceptable, especially in this era of the Precision Medicine Initiative (PMI), that currently our drugs are developed by, and optimized for, only for an exclusive segment of our citizens. We seek to shift this paradigm by strengthening the existing partnership between University of California at Riverside (UCR) and City of Hope Comprehensive Cancer Center (CoH-CCC). In this proposed P20, UCR and CoH-CCC will partner to develop the resources, infrastructure, and training programs necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. We anticipate that our P20 program will drive new collaborative R01 grants and K01 and T-type training grants. .

摘要美国的抗癌药物几乎完全由欧洲开发、测试和优化，美国人美国药物开发的差异是长期不平等的结果，在整个药物研发过程中。只有少数基础、转化和临床科学家是拉丁裔/西班牙裔或黑人/非裔美国人。不到2-5%的试验参与者是拉丁裔/西班牙裔或黑人/非裔美国人。然而，尽管缺乏数据，美国食品和药物管理局（FDA）还是批准了新药。美国食品药品监督管理局（FDA），随后规定为拉丁美洲/西班牙裔或黑人/非洲裔美国人患者，没有足够的测试。这是不可接受的，特别是在这个精准医学倡议（PMI）的时代，目前，我们的药物是由我们的公民中的一部分人开发和优化的。我们寻求通过加强加州大学之间的现有伙伴关系，滨江（UCR）和希望之城综合癌症中心（CoH-CCC）。在P20中，UCR 和CoH-CCC将合作开发必要的资源、基础设施和培训计划，培养下一代的治疗学研究人员，反映内陆南部的种族多样性加州。我们预计，我们的P20计划将推动新的合作R 01赠款和K 01和T型培训赠款。 .